These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 33895695)

  • 41. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
    Gampenrieder SP; Rinnerthaler G; Tinchon C; Petzer A; Balic M; Heibl S; Schmitt C; Zabernigg AF; Egle D; Sandholzer M; Singer CF; Roitner F; Hager C; Andel J; Hubalek M; Knauer M; Greil R
    Breast Cancer Res; 2021 Dec; 23(1):112. PubMed ID: 34906198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
    Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
    Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
    Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V;
    Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy.
    W DeClue R; Fisher MD; Gooden K; Walker MS; Le TK
    Future Oncol; 2023 Apr; 19(13):909-923. PubMed ID: 37191097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients.
    Taskindoust M; Thomas SM; Sammons SL; Fayanju OM; DiLalla G; Hwang ES; Plichta JK
    Ann Surg Oncol; 2021 Nov; 28(12):7441-7449. PubMed ID: 34050430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
    Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
    Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.
    Watanabe J
    Springerplus; 2015; 4():625. PubMed ID: 26543760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
    Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
    JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
    Statler AB; Hobbs BP; Wei W; Gupta A; Blake CN; Nahleh ZA
    Sci Rep; 2019 Dec; 9(1):18126. PubMed ID: 31792304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases.
    DeBusk K; Ike C; Lindegger N; Schwartz N; Surinach A; Liu Y; Forero-Torres A
    J Manag Care Spec Pharm; 2022 Jun; 28(6):657-666. PubMed ID: 35621719
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
    Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.
    Kuksis M; Gao Y; Tran W; Hoey C; Kiss A; Komorowski AS; Dhaliwal AJ; Sahgal A; Das S; Chan KK; Jerzak KJ
    Neuro Oncol; 2021 Jun; 23(6):894-904. PubMed ID: 33367836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
    Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
    Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
    Liede A; Sebby W; Miriyala AKR; Potluri R; Mazumder D; Ghosh A; Papademetriou E; Kilpatrick R; Tyczynski JE
    BMC Cancer; 2023 Jan; 23(1):78. PubMed ID: 36690978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
    BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
    Gampenrieder SP; Dezentjé V; Lambertini M; de Nonneville A; Marhold M; Le Du F; Cortés Salgado A; Alpuim Costa D; Vaz Batista M; Chic Ruché N; Tinchon C; Petzer A; Blondeaux E; Del Mastro L; Targato G; Bertucci F; Gonçalves A; Viret F; Bartsch R; Mannsbart C; Deleuze A; Robert L; Saavedra Serrano C; Gion Cortés M; Sampaio-Alves M; Vitorino M; Pecen L; Singer C; Harbeck N; Rinnerthaler G; Greil R;
    ESMO Open; 2023 Feb; 8(1):100747. PubMed ID: 36563519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
    Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
    Kazmi S; Chatterjee D; Raju D; Hauser R; Kaufman PA
    Breast Cancer Res Treat; 2020 Nov; 184(2):559-565. PubMed ID: 32808239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.